ICM
AMST icon

Invenomic Capital Management’s Amesite AMST Stock Holding History

Invenomic Capital Management’s Portfolio AMST Stock Details AMST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-22,643
Closed -$280K – 155
2021
Q4 		$280K Sell
22,643
-707
-3% -$12.1K 0.06% 137
2021
Q3 		$503K Buy
+23,350
New +$573K 0.16% 105

Other funds holding AMST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Invenomic Capital Management's AMST Position: Q1 2022 in Review

Invenomic Capital Management sold out of Amesite (AMST) in Q1 2022, closing a stake of 22,643 shares — an estimated $280K sold.

Invenomic Capital Management first reported a position in AMST in Q3 2021 and held it in 2 quarters. The position peaked at $503K in Q3 2021. 12 funds tracked by Wall St. Rank hold AMST as of Q1 2022.

  • Invenomic Capital Management reported no remaining Amesite position as of Q1 2022 after selling out during the quarter.
  • Invenomic Capital Management sold 22,643 Amesite shares in Q1 2022, an estimated $280K.
  • Invenomic Capital Management first reported a position in Amesite in Q3 2021 and held it in 2 quarters.
  • Invenomic Capital Management's Amesite position peaked at $503K in Q3 2021.
  • 12 funds tracked by Wall St. Rank held Amesite as of Q1 2022.

Based on Invenomic Capital Management's 13F filing for Q1 2022, filed 16 May 2022.